RxDoctor Payments Data

Julio Baco

General Practice · Mayaguez, PRNPI 1295818730

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $213,493 of the $267,706 with a category attached, or 79.7%. Viiv Healthcare Company accounts for 72.4% of it on its own, with 7 other manufacturers making up the rest. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$267,706in general payments, 2019–2025

Across 315 payments — averaging $849.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$194K
  • Johnson & Johnson$36K
  • Gilead$16K
  • Merck$13K
  • Janssen Products, LP$7K
  • Theratechnologies Inc.$972
  • plus $235 from 2 others

What the payments were for

  • Consulting fees$33,09512%
  • Speaking & faculty fees$213,49380%
  • Travel & lodging$12,6935%
  • Food & beverage$8,2303%
  • Education$1960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company174$193,718
Johnson & Johnson59$36,363
Gilead27$16,065
Merck27$13,213
Janssen Products, LP15$7,140
Theratechnologies Inc.6$972
AbbVie6$222
GSK1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$267,706 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine173$521,117
TivicayDolutegravir Sodium90$229,557
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf36$195,830
PrezcobixDarunavir/Cobicistat74$181,577
DescovyEmtricitabine/Tenofov Alafenam52$118,413
TriumeqAbacavir/Dolutegravir/Lamivudi30$112,373
JulucaDolutegravir/Rilpivirine26$92,021
Isentress HdRaltegravir Potassium31$65,560
BiktarvyBictegrav/Emtricit/Tenofov Ala11$43,580
PifeltroDoravirine20$35,060
Estazolam12$866
Estradiol13$395
Spironolactone13$385
Gabapentin20$302
FenofibrateFenofibrate Nanocrystallized19$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca$193,718$955,068319 claims
Janssen Products, LPSymtuza$7,140$195,83036 claims
Johnson & JohnsonPrezcobix$36,363$181,57774 claims
GileadDescovy, Biktarvy$16,065$161,99363 claims
MerckIsentress Hd, Pifeltro$13,213$100,62051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →